RE: Interesting buying13 Nov 2023 13:06
What are the potential areas this could fall over?
They stated Q1-24 EBITDA should be +£3.4m, which is a net +£11m EBITDA swing from Q1-23. Momentum was said to continue, so can only imagine at least a positive EBITDA number around this. Cash generated from operations would have been significant last year but was held back due to £5m+ in legal fees, etc, so I would expect a positive operating cash flow number. They do have c£20m debt to pay off their medichem acquisition, but this has been delayed to 2025, so plenty of headroom there! I'm sure there is something, as this co always surprises, but maybe not?! Thoughts?